Cencora, Inc. (NYSE:COR) Holdings Lifted by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. boosted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 22.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,225 shares of the company's stock after acquiring an additional 6,440 shares during the quarter. Cencora comprises about 0.4% of Black Creek Investment Management Inc.'s investment portfolio, making the stock its 20th biggest holding. Black Creek Investment Management Inc.'s holdings in Cencora were worth $7,914,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of COR. Hickory Asset Management Inc. acquired a new stake in shares of Cencora during the fourth quarter worth $572,000. Sylvest Advisors LLC acquired a new stake in Cencora during the 4th quarter worth about $1,105,000. Insight Wealth Strategies LLC lifted its stake in Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after buying an additional 11,232 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after buying an additional 1,995 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock worth $1,583,000 after acquiring an additional 2,928 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at $85,680,732.63. This represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. The trade was a 21.96 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 30,675 shares of company stock valued at $8,034,778. Company insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

COR has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday. Wells Fargo & Company raised their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $284.20.

Remove Ads

Cencora Stock Up 1.9 %

Cencora stock opened at $284.46 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The firm's fifty day simple moving average is $260.27 and its 200-day simple moving average is $245.01. The company has a market capitalization of $55.16 billion, a P/E ratio of 40.46, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.